Certolizumab

Phase 3Monoclonal antibody

Johnson & Johnson

Certolizumab is one of 162 small molecule programs targeting Rheumatic Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

161

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatic DiseaseRecruiting

OsteomyelitisActive, not recruiting

Atopic DermatitisNot yet recruiting

Psoriatic ArthritisActive, not recruiting

RecurrentRecruiting

Rheumatic DiseasePhase 2

Recruiting

OsteomyelitisPreclinical

Active, not recruiting

Atopic DermatitisPhase 3

Not yet recruiting

Psoriatic ArthritisPreclinical

Active, not recruiting

RecurrentPhase 3

Recruiting

Competition

Competitive Landscape

116 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

1 2

Cytosar

Teva

Phase 3

1 3

Adtralza

LEO Pharma

Phase 3

17 4

Amlitelimab

Sanofi

Phase 3

2 5

DUPIXENT

Regeneron

Phase 3

1 6

Certolizumab

Johnson & Johnson

Phase 3

1 7

ICP-332

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

2 8

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

5 9

MG-K10

SShanghai Mabgeek Biotech.Co.Ltd

Phase 3

2 10

LNK01001

LLynk Pharmaceuticals Co., Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Rheumatic Disease

NCT07138898

Q1 2029

Phase 3Recruiting

Rheumatoid Arthritis

NCT03414502

Q2 2029

Phase 3Recruiting

Recurrent

NCT05930613

Q2 2030

Post-ApprovalNot yet recruiting

Atopic Dermatitis

NCT07352566

Clinical

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)

Completed·UUniversity of Rochester··NCT01098201·5 enrolled

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting·UUniversity of Nebraska·Phase 3·NCT03414502·400 enrolled

A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT06028438·103 enrolled

Lung Adenocarcinoma1 trial

Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02120807·30 enrolled

Osteomyelitis1 trial

CHronic Nonbacterial Osteomyelitis International Registry

Recruiting·SSeattle Children's Hospital··NCT04725422·2,000 enrolled

Psoriatic Arthritis1 trial

Ultrasound Enthesitis Response in Psoriatic Arthritis

Completed·BBelfast Health and Social Care Trust··NCT03955861·80 enrolled

Inflammation1 trial

Lipids, Inflammation, and CV Risk in RA

Completed·—··NCT02714881·74 enrolled

6 more indications

Atopic Dermatitis1 trial

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07352566·10 enrolled

Ankylosing Spondylitis1 trial

Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Unknown status·JJagiellonian University·Phase 4·NCT02132234·100 enrolled

Crohn's Disease1 trial

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

Terminated·—··NCT01582568·1 enrolled

Recurrent1 trial

Certolizumab in Recurrent Implantation Failure (RIF)

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05930613·161 enrolled

Lung Cancer1 trial

Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04991025·60 enrolled

Rheumatic Disease1 trial

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Recruiting·NNYU Langone Health·Phase 2·NCT07138898·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Certolizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Certolizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Certolizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Certolizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2029

Q2 2029

Q2 2030

Trials by Indication[1]

Rheumatoid Arthritis3 trials

Lung Adenocarcinoma1 trial

Osteomyelitis1 trial

Psoriatic Arthritis1 trial

Inflammation1 trial

Atopic Dermatitis1 trial

Ankylosing Spondylitis1 trial

Crohn's Disease1 trial

Recurrent1 trial

Lung Cancer1 trial

Rheumatic Disease1 trial

References

Drug Info

Quick Facts

Related News